Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H18N4O |
Molecular Weight | 378.4259 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=C(C=CC=C2)C3=C1C4=C(C5=CC=CC=C5N4CCC#N)C6=C3C(=O)NC6
InChI
InChIKey=VWVYILCFSYNJHF-UHFFFAOYSA-N
InChI=1S/C24H18N4O/c1-27-17-9-4-2-7-14(17)20-21-16(13-26-24(21)29)19-15-8-3-5-10-18(15)28(12-6-11-25)23(19)22(20)27/h2-5,7-10H,6,12-13H2,1H3,(H,26,29)
Molecular Formula | C24H18N4O |
Molecular Weight | 378.4259 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://adisinsight.springer.com/drugs/800011324Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8486620 | https://www.ncbi.nlm.nih.gov/pubmed/21366551 | https://www.ncbi.nlm.nih.gov/pubmed/16956345
Sources: http://adisinsight.springer.com/drugs/800011324
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8486620 | https://www.ncbi.nlm.nih.gov/pubmed/21366551 | https://www.ncbi.nlm.nih.gov/pubmed/16956345
Indolocarbazole GO-6976 inhibited the calcium-dependent protein kinase C (PKC) isozymes alpha and beta 1. As PKC is a central enzyme that modulates numerous biological functions GO-6976 is extensively used as a tool for studying the involvement of PKC in signal transduction pathways. GO6976 was originally synthesized by Goedecke (formerly a subsidiary of Warner-Lambert, now Pfizer) in Germany. Preclinical investigations carried out by Goedecke have been for the potential treatment of HIV infections. Preclinical research with GO 6976 had been conducted by Biomol Inc. and Calbiochem in the USA as a potential treatment for cancer. No further information has been available for the compound therefore it is assumed that development has been discontinued. In addition to GO-6976 inhibition of PKC, it was reported that GO-6976 also inhibits JAK 2 and FLT3 tyrosine kinases and non-kinase transmembrane guanylyl cyclase.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24959860 | https://www.ncbi.nlm.nih.gov/pubmed/18501877
Curator's Comment: GO-6976 is CNS active in animals. No human data available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL299 |
2.3 nM [IC50] | ||
Target ID: CHEMBL3045 |
6.2 nM [IC50] | ||
Target ID: CHEMBL2971 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16956345 |
|||
Target ID: CHEMBL1974 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16956345 |
|||
Target ID: CHEMBL1988 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21366551 |
|||
Target ID: CHEMBL2156 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21366551 |
380.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Putative conventional protein kinase C inhibitor Gödecke 6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole] stimulates transglutaminase activity in primary mouse epidermal keratinocytes. | 2002 Jul |
|
Differential modulation of CaV2.3 Ca2+ channels by Galphaq/11-coupled muscarinic receptors. | 2004 Feb |
|
Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. | 2005 Apr |
|
Cigarette smoke extract increases C5a receptor expression in human bronchial epithelial cells. | 2005 Jul |
|
Hypotonic shock mediation by p38 MAPK, JNK, PKC, FAK, OSR1 and SPAK in osmosensing chloride secreting cells of killifish opercular epithelium. | 2005 Mar |
|
Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury. | 2005 May |
|
Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT. | 2005 Oct |
|
Corticotropin-releasing hormone inhibits progesterone production in cultured human placental trophoblasts. | 2006 Dec |
|
Activation of ROS/NF-kappaB and Ca2+/CaM kinase II are necessary for VCAM-1 induction in IL-1beta-treated human tracheal smooth muscle cells. | 2009 May 15 |
|
Nucleotide oligomerization domain 1 is a dominant pathway for NOS2 induction in vascular smooth muscle cells: comparison with Toll-like receptor 4 responses in macrophages. | 2010 Aug |
|
Angiotensin II inhibits activity of human organic anion transporter 3 through activation of protein kinase Calpha: accelerating endocytosis of the transporter. | 2010 Feb 10 |
|
Zinc-triggered induction of tissue plasminogen activator by brain-derived neurotrophic factor and metalloproteinases. | 2011 Sep |
|
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. | 2013 Apr 15 |
|
Oxidative stress parameters induced by exposure to either cadmium or 17β-estradiol on Mytilus galloprovincialis hemocytes. The role of signaling molecules. | 2014 Jan |
Sample Use Guides
Inflammation-induced multinucleation in cultured microglia was prevented by a protein kinase C (PKC) inhibitor GO-6976 (100 nM).
Follicle-stimulating hormone (FSH ) significantly induced follicle-enclosed oocytes (FEOs) meiotic resumption, however, the induced effect of FSH was dose-dependently inhibited by Gö6976, and 100 nM Gö6976 completely blocked FSH function in oocyte meiotic resumption.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 02:31:05 UTC 2022
by
admin
on
Sat Dec 17 02:31:05 UTC 2022
|
Record UNII |
B9IQO7JZ16
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
136194-77-9
Created by
admin on Sat Dec 17 02:31:05 UTC 2022 , Edited by admin on Sat Dec 17 02:31:05 UTC 2022
|
PRIMARY | |||
|
Go 6976
Created by
admin on Sat Dec 17 02:31:05 UTC 2022 , Edited by admin on Sat Dec 17 02:31:05 UTC 2022
|
PRIMARY | |||
|
DTXSID70159731
Created by
admin on Sat Dec 17 02:31:05 UTC 2022 , Edited by admin on Sat Dec 17 02:31:05 UTC 2022
|
PRIMARY | |||
|
3501
Created by
admin on Sat Dec 17 02:31:05 UTC 2022 , Edited by admin on Sat Dec 17 02:31:05 UTC 2022
|
PRIMARY | |||
|
51913
Created by
admin on Sat Dec 17 02:31:05 UTC 2022 , Edited by admin on Sat Dec 17 02:31:05 UTC 2022
|
PRIMARY | |||
|
B9IQO7JZ16
Created by
admin on Sat Dec 17 02:31:05 UTC 2022 , Edited by admin on Sat Dec 17 02:31:05 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |